Literature DB >> 16226118

Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case.

Simone Heiss1, Martin Erdel, Eberhard Gunsilius, David Nachbaur, Alexandar Tzankov.   

Abstract

We report on a patient fulfilling the diagnostic criteria of unclassifiable myelodysplastic/myeloproliferative diseases with prominent erythropoietic hyperplasia/dysplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24). The patient presented with B-symptoms, erythroblastemia, thrombopenia, marked eosinophilia, presence of myeloid precursors in the peripheral blood, and decreased erythropoietin level. Nodular peritrabecular polymorphous blasts, dysplastic megakaryocytes, and a diffuse argyrophilic fibrosis were detected in the trephine bone marrow biopsy. Immunohistochemically, the blasts stained positively for glycophorin C and hemoglobin A; the proliferation fraction was nearly 90% in the Ki-67 stain. Expression of the phosphorylated Janus kinase 2 was detected in almost all megakaryocytes and in isolated erythroblast islets, suggesting a probable activation of Janus kinase 2, the jak-2 gene being mapped on 9p24. Ten months after initial diagnosis, the disease progressed to frank acute erythroid leukemia. We report for the first time a myelodysplastic/myeloproliferative disease (erythroid preleukemia) accompanied by the specific chromosomal aberration t(8;9)(p23;p24), distinct histopathology, and clinical and laboratory symptoms, and progress to acute erythroid leukemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226118     DOI: 10.1016/j.humpath.2005.07.020

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2018-08-21       Impact factor: 4.064

2.  Enhanced growth of myelodysplastic colonies in hypoxic conditions.

Authors:  James Edwin Thompson; Joseph Patrick Conlon; Xiaowei Yang; Patricia Vanessa Sanchez; Martin Carroll
Journal:  Exp Hematol       Date:  2007-01       Impact factor: 3.084

Review 3.  Updates on eosinophilic disorders.

Authors:  Alexandar Tzankov; Kaaren K Reichard; Robert P Hasserjian; Daniel A Arber; Attilio Orazi; Sa A Wang
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

4.  Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo.

Authors:  J A Kennedy; F Barabé; B J Patterson; J Bayani; J A Squire; D L Barber; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

5.  Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.

Authors:  Kuan-Po Huang; Andrew J Chase; Nicholas C P Cross; Andrea Reiter; Tzu-Ying Li; Tso-Fu Wang; Sung-Chao Chu; Xuan-Yin Lu; Chi-Cheng Li; Ruey-Ho Kao
Journal:  Int J Hematol       Date:  2008-07-02       Impact factor: 2.490

6.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

7.  PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.

Authors:  Henry G Kaplan; Ruyun Jin; Carlo B Bifulco; James M Scanlan; David R Corwin
Journal:  Oncologist       Date:  2022-08-05       Impact factor: 5.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.